Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug 25:7:117-125.
doi: 10.2147/OAJC.S97013. eCollection 2016.

Contraceptive options for women with premenstrual dysphoric disorder: current insights and a narrative review

Iñaki Lete  1   2   3 , Oihane Lapuente  1   2
Affiliations
Review

Contraceptive options for women with premenstrual dysphoric disorder: current insights and a narrative review

Iñaki Lete et al. Open Access J Contracept. .

Abstract

Premenstrual syndrome and its most severe form, premenstrual dysphoric disorder (PMDD), are two well-defined clinical entities that affect a considerable number of women. Progesterone metabolites and certain neurotransmitters, such as gamma-aminobutyric acid and serotonin, are involved in the etiology of this condition. Until recently, the only treatment for women with PMDD was psychoactive drugs, such as selective serotonin reuptake inhibitors. Several years ago, there has been evidence of the beneficial role of combined hormonal contraceptives in controlling PMDD symptoms. Oral combined hormonal contraceptives that contain drospirenone in a 24+4-day regimen are the only drugs that have been approved by US Food and Drug Administration for the treatment of PMDD, but there is scientific evidence that other agents, with other formulations and regimens, could also be effective for the treatment of this condition. However, it remains unclear whether the beneficial effect of combined hormonal contraceptives is associated with the type of estrogen or progestogen used or the treatment regimen.

Keywords: drospirenone; estradiol; hormonal contraceptives; premenstrual dysphoric disorder; premenstrual syndrome.

PubMed Disclaimer

Conflict of interest statement

Disclosure Iñaki Lete has a financial relationship (lecturer, member of advisory boards, and/or consultant) with MSD, Teva, Adamed, HRA Pharma, and Nordic Pharma. Oihane Lapuente reports no conflicts of interest in this work.

References

    1. Halbreich U. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder clinical procedures and research perspectives. Gynecol Endocrinol. 2004;19(6):320–324. - PubMed
    1. Hylan TR, Sundell K, Judge R. The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France. J Womens Health Gend Based Med. 1999;8(8):1043–1052. - PubMed
    1. Campbell EM, Peterkin D, O’Grady K, Sanson-Fisher R. Premenstrual symptoms in general practice patients. Prevalence and treatment. J Reprod Med. 1997;42(10):637–646. - PubMed
    1. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med. 2002;32(01):119–132. - PubMed
    1. World Health Organization . Tenth Revision of the International Classification of Diseases (ICD-10) Geneva: World Health Organization; 1966. Mental, behavioural and developmental disorders.

LinkOut - more resources